PERSEPT 3 A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta recombinant human FVIIa in perioperative care in subjects with haemophilia A or B with inhibitors

M EscobarJ LuckY AverianovJ DucoreM FernandezJohnny Mahlangu2023-04-132023-04-13WOS1351-8216https://hdl.handle.net/10539/35011PERSEPT 3 A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta recombinant human FVIIa in perioperative care in subjects with haemophilia A or B with inhibitors